Kuehnle AgroSystems is based in Hawaii, leveraging its patented “dark fermentation” process and proprietary non-GMO microalgal strains to produce natural astaxanthin © Kuehnle AgroSystems
Astaxanthin, a powerful antioxidant and red-orange carotenoid pigment, is naturally present in microalgae, salmon and shrimp. Valued for its human health benefits and as a key feed ingredient for salmon and other aquaculture species, it is currently produced either through chemical synthesis for aquaculture or by cultivating the microalga Haematococcus for human health applications.
Corbion and Kuehnle AgroSystems (KAS) aim to provide a natural, algae-derived alternative produced through controlled fermentation of non-GMO, heterotrophic Haematococcus – the primary natural source of astaxanthin.
The partnership will focus on developing an esterified form of astaxanthin, rich in the most bioavailable isomer, delivering superior antioxidant performance, enhanced stability and fat solubility. Designed for both the human and animal nutrition markets, the product is particularly well-suited for nutraceuticals and aquaculture applications.
By combining KAS’s advanced fermentation platform and proprietary non-GMO algae strains with Corbion’s industrial production capabilities, regulatory and go-to-market expertise, the two companies aim to bring this innovation to market at scale.
“This partnership reinforces our commitment to sustainable, science-based solutions. KAS’ technology offers a strong foundation to deliver high-quality natural astaxanthin to customers looking for a clean-label alternative,” said Robert Jan de Voogd, general manager of algae ingredients for North America at Corbion, in a press release.
“We’re proud to collaborate with Corbion to scale our technology and make premium algae-derived antioxidants more accessible worldwide,” said Claude Kaplan, chief executive officer of KAS.
Development and technical transfer have already begun, with further updates to follow as the project progresses.
